View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aedifica: Conference call highlights. Basic-Fit: Belgian VAT increase for culture, sports and takeaway meals postponed. BE Semiconductor Industries: 4Q25 Preview, incremental strength. Kendrion: Preview - Clean into 2026. Magnum Ice Cream Company: Acquisition of Kwality Wall's launched. Retail Estates: Re-letting progress highlights portfolio quality. Semi Equipment: AMAT readthrough strength. Universal Music Group: EU Commission approves UMG's Downtown acquisition, requires full Curve Ro...

Jason Kalamboussis ... (+3)
  • Jason Kalamboussis
  • Reg Watson
  • CFA

Euronext/(euro) Next Steps/BUY

This report reviews Euronext's progress against its 2027 strategy targets and we conclude that the company is on track to beat its targets as it is well ahead of plan with more growth initiatives in the pipeline. As a result, our EPS forecasts diverge significantly from Bloomberg consensus in 2026 and 2027 because we assume that Euronext delivers on these growth plans and undertakes an additional €1.1bn of share buybacks in 2026-27F in order to maintain net debt/EBITDA at the mid-point of the gu...

Symrise AG: 1 director

A director at Symrise AG bought 2,080 shares at 72.394EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ahold Delhaize: Serbia regulation to be litigated at international level. CM.com: Preview FY25. dsm-firmenich: At last! Exor: Stellantis shares fall sharply on €22bn turnaround plan, writeoff. Euronext: 2026 starting strong. Proximus: €275m impairment at Proximus Global

 PRESS RELEASE

Euronext announces volumes for January 2026

Euronext announces volumes for January 2026 Euronext announces volumes for January 2026 Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 6 February 2026 – Euronext, the leading European capital market infrastructure, today announced trading volumes for January 2026. Monthly and historical volume tables are available at this address: CONTACTS   ANALYSTS & INVESTORS – Investor Relations        Judith Stein         97         Margaux Kurver         03         MEDIA –   Europe        Andrea Monzani          13          Sandra Machado         7 Belgium        M...

 PRESS RELEASE

Euronext completes €250 million share repurchase programme

Euronext completes €250 million share repurchase programme Euronext completes €250 million share repurchase programme Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 29 January 2026 – Euronext today announced that it has completed the share repurchase programme announced on 6 November 2025. Between 18 November 2025 and 27 January 2026, 1,967,993 shares, or approximately 1.90% of Euronext’s share capital, were repurchased at an average price of €127.03 per share. This repurchase programme was executed by a financial intermediary in compliance with applicable rules and ...

 PRESS RELEASE

BioNTech ernennt Kylie Jimenez zur neuen Personalvorständin

BioNTech ernennt Kylie Jimenez zur neuen Personalvorständin Mainz, Deutschland, 28. Januar 2026 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Kylie Jimenez mit Wirkung zum 1. März 2026 zur Personalvorständin (Chief People Officer, „CPO“) ernannt hat. Die Ernennung folgt konsequent der strategischen Ausrichtung BioNTechs, um sich bis 2030 zu einem Onkologieunternehmen mit mehreren zugelassenen Produkten zu entwickeln, und unterstreicht die Bedeutung der globalen, hochqualifizierten Belegschaft des Unternehmens, um dieses Ziel z...

 PRESS RELEASE

BioNTech Announces Appointment of Kylie Jimenez to Management Board as...

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer (“CPO”) effective March 1, 2026. The appointment is in line with BioNTech’s strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jim...

Anthony Dick ... (+2)
  • Anthony Dick
  • Michael Foundoukidis

ODDO : Une nouvelle année à valeur de test pour le secteur, une de plu...

La saison de résultats ne devrait pas apporter de mauvaises surprises concernant la fin 2025 (cf. messages rassurants lors de nos conférences et des pre-close calls) mais les perspectives 2026 devraient rester prudentes face au manque de visibilité. Face à cela, les managements vont à nouveau concentrer leurs efforts sur les leviers internes et l’agilité mais le sentiment sur le secteur pourrait rester fragile à court terme, nous conduisant à maintenir nos estimations prudentes et une approche o...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch